Search results
15 wrz 2022 · Complete thrombus resolution was achieved in 62.3% (n=99) at a median of 103 days (interquartile range, 32–392 days). 17 Recurrence of thrombus or an increase in LV thrombus area was observed in 14.5% (n=23), a finding associated with poor adherence, prothrombotic conditions, and increased mortality. 17.
- View EPUB
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Linda S. Williams
The WEAVE prospective registry (Wingspan Stent System Post...
- PDF/Epub
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Trial
Background—The Randomized Evaluation of Long-term...
- Results From the GEIST
Left ventricular (LV) thrombus formation is a well‐known...
- Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Objective: Takotsubo syndrome (TTS) is characterized by...
- Stroke
National Center. 7272 Greenville Ave.Dallas, TX 75231....
- Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a potentially life-threatening...
- View EPUB
Results: Among 297 patients with LVT diagnosed by echocardiography, 191 patients with follow-up echocardiography were included in our study. The mean age was 64 years, 44 (23%) were female, and 131 patients (66.4%) had ischemic cardiomyopathy.
17 kwi 2023 · Patients with left ventricular thrombus (LVT) resolution can have LVT recurrence and risk for thromboembolism. However, these outcomes after LVT resolution are not well known. We aimed to assess the prevalence, risk factors, and clinical outcomes for LVT recurrence in patients with LVT resolution to inform follow‐up and treatment.
27 cze 2023 · Management Options for LVT Persistence. In large observational studies, the rate of thrombus resolution at 6 months ranged from more than 80% to as low as 30%. 26,40 In the setting of persistent LVT, most studies continued anticoagulation or switched to a different anticoagulant (Table 2).
1 maj 2023 · Echocardiographic outcomes evaluated included resolution of thrombus size and time to complete thrombus resolution. Clinical outcomes included mortality, thromboembolic complications, and bleeding complications.
In the contemporary era, the most common precipitating factor for LV thrombus is HF; most patients are not on GDMT at the time of diagnosis. Warfarin remains the most commonly prescribed anticoagulant. Efficacy and safety of DOACs in treatment of LV thrombus requires a prospective clinical trial.
23 wrz 2022 · If OAC is initiated, a treatment duration might be 1–3 months, depending on bleeding risk. On the basis of reasonable data and evidence, post-MI patients with LV thrombus should be treated with OAC, typically for a duration of 3 months.
